Synergistic in vitro activity of AZT with alpha and gamma interferon (IFN) in chronic myeloid leukemia (CML) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Synergistic in vitro activity of AZT with alpha and gamma interferon (IFN) in chronic myeloid leukemia (CML) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1800 1993. Unique Identifier : AIDSLINE MED/93692741
Tosi P; Visani G; Ottaviani E; Tura S; Inst. Hematology 'Seragnoli', Italy

Abstract: We have reported that the antineoplastic activity of AZT is increased by drugs that inhibit de novo dTMP synthesis, such as 5-fluorouracil, methotrexate and hydroxyurea. In the present study, we tested the combinations of AZT + alpha IFN and AZT + gamma IFN on in vitro growth of the human acute-phase CML cell line K562. After 72 hr incubation both the combinations were synergistic in inhibiting cell growth, as demonstrated by isobologram analysis of the data. [3H] AZT incorporation into DNA was increased by 50% and 222% by alpha and gamma IFN, respectively. The addition of 50 uM thymidine to the culture medium reduced the cytotoxicity of the drug combinations to the degree observed with each compound alone and the increased incorporation of AZT into DNA was completely reverted. Preliminary data on human CML-CFU-GM show that alpha and gamma IFN are able to decrease the IC50 of AZT by 90% and 79%, respectively.
Keywords: *Interferon Type II/PHARMACOLOGY *Interferon-alpha/PHARMACOLOGY *Leukemia, Myeloid, Chronic/DRUG THERAPY *Zidovudine/PHARMACOLOGYKWDinterferontypeii/pharmacologyKWDinterferon-alpha/pharmacologyKWDleukemia,myeloid,chronic/drugtherapyKWDzidovudine/pharmacology
931130
M93B5841

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .